The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway

Haass, Christian, Lemere, Cynthia A., Capell, Anja, Citron, Martin, Seubert, Peter, Schenk, Dale, Lannfelt, Lars, Selkoe, Dennis J.·1995·Nature Medicine
DOI 10.1038/nm1295-1291

Cited by (598)

Items 501–598 of 598

  1. Isogenic cortical organoids enable precision targeting of APP variant-specific pathways in Alzheimer’s disease
    Tobias Graß, Ilyas Mehmet Cosacak, Alban Ordureau, Feodor D. Price, Shrutika Kavali, A Caldarelli, Min N. Qiao, Badri Narayan Vardarajan, João A. Paulo, Michele Marass et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  2. Presenilin und β-Amyloid: Schlüsselmoleküle der Alzheimerschen Erkrankung
    Ch. Haass · 1998 · Springer eBooks
  3. Lésions sélectives de deux populations de neurones affectées dans la maladie d’Alzheimer : impact sur les performances cognitives et l’histopathologie des souris tg2576
    Nour Yassine · 2011 · OpenGrey (Institut de l'Information Scientifique et Technique)
  4. Targeting Early Stages of Alzheimer’s Disease in a Transgenic Model
    Anna Lord · 2009 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
  5. Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease
    Todd Eliot Golde · 2007 · Blue books of neurology
  6. Effects of A-beta immunotherapy and Omega-3 fatty acid administration in Alzheimer's transgenic mice
    Maren Jensen · 2006
  7. INDUCTION OF THE HEAT SHOCK RESPONSE TO PROTECT AGAINST POLYGLUTAMINE DISEASES AND THE ROLE OF PROTEIN SUMOYLATION IN LAMINOPATHIES AND ALZHEIMER'S DISEASE
    Yu-Qian Zhang · 2008 · UKnowledge (University of Kentucky)
  8. Amyloid precursor protein with the Alzheimer´s disease 670/671 mutation : Animal and cellular models
    Ewa Kloskowska · 2008 · Figshare
  9. CHAPTER 5.6 Identification and functional analysis of genes and genetic risk factors in Alzheimer's disease
    Chris De Jonghe, Christine Van Broeckhoven · 1999 · Techniques in the behavioral and neural sciences
  10. Identification of a BACE dimer and characterization of its biochemical and enzymatic properties
    Gil G. Westmeyer · 2006
  11. Role of the 39-kDa receptor-associated protein (RAP) in Alzheimer's disease
    Hoang, T · 2012 · UTAS Research Repository
  12. Regulation of expression and cellular release of acetylcholinesterase
    David A. Hicks · 2013 · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
  13. Characterization of proteins involved in the production of β-Amyloid peptides and tau hyperphosphorlation in Familial Alzheimer’s Disease
    Barrera Ocampo, Álvaro Andrés · 2012
  14. Genetics of early-onset Alzheimer disease
    Peter St George‐Hyslop · 2001 · Birkhäuser Basel eBooks
  15. Pathogenic mechanisms of the Arctic Alzheimer mutation.
    Charlotte Sahlin · 2007 · Uppsala University Publications (Uppsala University)
  16. The Effect of Acute LPS-Induced Immune Activation and Brain Insulin Signaling Disruption in a Diabetic Model of Alzheimer's Disease
    Andrew S. Murtishaw · 2020 · Digital Scholarship - UNLV (University of Nevada Reno)
  17. The implications of genetic studies on the pathogenesis of Alzheimer's disease
    Hidenao Sasaki · 1998 · Neuropathology
  18. Proteolysis of Mutant Gene Products are Key Mechanisms in Neurodegenerative Diseases
    VIVIAN Y. H. HOOK · 2002 · Springer eBooks
  19. Characterisation of transgenic mouse models of Alzheimer's disease
    Lindsay Graham · 2011 · OpenGrey (Institut de l'Information Scientifique et Technique)
  20. Modulation of BACE1 by a novel sorting nexin in Alzheimer's disease
    Hirokazu Okada · ProQuest Demo Repository
  21. Molecular Processing Pathways of β-Amyloid Precursor Protein: Therapeutic Implications
    Christian Haass · 1996 · Springer eBooks
  22. Synergistic effect of N-terminal pyroglutamyl amyloid ß protein in Alzheimer's disease and in normal aging
    Ying-Chuan Wang, Ren‐Jing Huang, Shieh-Ding Wu, Chung Shan · 2009
  23. Signaltransduktion des humanen Neuropeptidrezeptors SorLA - γ-Secretase-abhängige Freisetzung der Intrazellulärdomäne des
    Christopher Böhm · 2005
  24. Dynamics of amyloid plaque formation in Alzheimer’s Disease
    Joanna F McCarter · 2014 · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)
  25. Determining the Transmembrane Topology of the Presenilins
    Gopal Thinakaran, Andrew Doan · 2003 · Humana Press eBooks
  26. MALATTIA DI ALZHEIMER E DEGENERAZIONE LOBARE FRONTOTEMPORALE: RICERCA DI MUTAZIONI AUTOSOMICHE DOMINANTI E ANALISI GENETICA E FUNZIONALE DI GENI CANDIDATI
    María Serpente · 2013 · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)
  27. Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
    Pedro Dionísio · 2014 · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
  28. An Investigation into the Role of Iron, Copper, and Gender in a Transgenic Mouse Model of Alzheimer's Disease.
    Caitlin M. Groeber · 2013
  29. Der Einfluss des Geschlechts auf die Neuronenanzahl in einem APP/PS1- doppeltransgenen Mausmodell der Alzheimer-Krankheit
    Abteilung für Neurobiologie · 2006
  30. Pathological Consequences of Aβ From Extracellular to Intraneuronal
    Michael R. D’Andrea · 2016 · Elsevier eBooks
  31. Development of Neoepitope Antibodies Against the β-Secretase Cleavage Site in the Amyloid Precursor Protein
    Carol W. Gray, Eric H. Karran · 2003 · Humana Press eBooks
  32. Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
    Faculdade De Farmácia · 2014
  33. Activity-inducible kinase Plk2 regulates APP amyloidogenic processing and Abeta mediated synaptic depression
    YeunKum Lee · 2012 · Georgetown University-Graduate School of Arts & Sciences
  34. Analyse des neuen Proteins TMEM59 und seiner Funktion in dem Transport und der Prozessierung des Amyloid-Vorläufer-Proteins
    Dissertation der Fakultät, Ludwig-Maximilian-Universität München · 2008
  35. Therapeutic Targeting of Aβ42
    Todd Eliot Golde, Christian B. Lessard, Yong Ran · 2016 · Elsevier eBooks
  36. Pathological Changes in the Elderly Human Brain
    David M. A. Mann · 1997 · Springer eBooks
  37. Biochemical Characterization of Amyloid Precursor Protein
    Weiming Xia · 2004 · CRC Press eBooks
  38. A characterization of deficits associated with loss of NCB5OR in the mouse brain
    Matthew A. Stroh · 2016 · KU ScholarWorks (The University of Kansas)
  39. Dissecting the role of Proteolysis and Cytoskeleton remodeling in protein aggregation related diseases
    Catarina Santos Silva · 2015 · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
  40. de dans la maladie d'Alzheimer
    Jean Sévalle · 2009
  41. EFFECTS OF THE NOVEL IDO INHIBITOR DWG-1036 ON THE BEHAVIOUR AND NEUROCHEMISTRY OF THE TRIPLE TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE
    Emre Fertan · 2017 · DalSpace (Dalhousie University)
  42. Lessons From Using Genome Editing to Create a Faithful Model of a Novel Congenital Anemia
    Xiaoli Mi · 2018 · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
  43. Analyse structurale et fonctionnelle de la préséniline-1 humaine : implications dans la maladie d'Alzheimer
    Sébastien S. Hébert · 2003 · Corpus Université Laval (Université Laval)
  44. The interplay between mitochondria-endoplasmic reticulum contacts and Alzheimer’s disease
    Santos Leal, Nuno João · 2019 · Figshare
  45. Genomics of Alzheimer’s disease
    Roger N. Rosenberg, Doris Lambracht‐Washington, Gang Yu, Weiming Xia · 2020 · Elsevier eBooks
  46. Molecular basis of amyloid-β chaperone activity of lipocalin-type prostaglandin D synthase (L-PGDS)
    Bhuvaneswari Kannaian · 2019
  47. Targeting Alzheimer’s disease and related dementias with CRISPR and human pluripotent stem cell technologies
    Andrew A. Sproul · 2021 · Elsevier eBooks
  48. Lexikalischer Teil
    Regine Witköwski, Otto Prokop, Eva Ullrich, Gundula Thiel · 2003 · Springer eBooks
  49. Etiological Considerations
    David M. A. Mann · 1997 · Springer eBooks
  50. Spinosin
    Jessica Pandohee, Mohamad Fawzi Mahomoodally · 2020 · Elsevier eBooks
  51. Animal Models of Amyloid/PS-1 Pathology
    Akihiko Takashima · 2011 · Royal Society of Chemistry eBooks
  52. Maladie d’Alzheimer, peptides β-amyloïdes et système ubiquitine-protéasome
    Philippe Yves Rémy Simon, Johanna Bus, Renaud David · 2023 · médecine/sciences
  53. Sterol Biomarker Discovery In Neurodegenerative Diseases
    Manuela Pacciarini · 2023
  54. Tau Transgenic Mouse Models in Therapeutic Development
    Hanno M. Roder · 2009 · Springer eBooks
  55. Human genetics: Establishment of cause-and-effect relationships
    Takaomi C. Saido · 2024 · Elsevier eBooks
  56. Genomics of Alzheimer’s disease
    Roger N. Rosenberg, Doris Lambracht‐Washington, Gang Yu, Weiming Xia · 2024 · Elsevier eBooks
  57. The role of ROS in cardiovascular and neurological disorders
    Shyamal K. Goswami · 2025 · Elsevier eBooks
  58. Etude de la dynamique de tau dans le compartiment synaptique dans un contexte physiologique et pathologique exemple de la maladie d'Alzheimer
    Marie‐Lise Frandemiche · 2013 · theses.fr (ABES)
  59. The role of Hsp20 in Alzheimer's disease
    Ryan T. Cameron · 2014 · Enlighten: Theses (The University of Glasgow)
  60. The Processing of Amyloid Precursor Protein in the Central Nervous System of Humans and Rhesus Macaques
    Justyna A. Dobrowolska Zakaria · 2013 · Open Scholarship Institutional Repository (Washington University in St. Louis)
  61. Characterisation of visuospatial memory in the Tg2576 model of Alzheimer's disease
    Gemma Hale · 2007 · ORCA Online Research @Cardiff (Cardiff University)
  62. Untersuchungen zur intrazellulären Lokalisation der γ-Sekretase
    Stéphanie Schmitt · 2011 · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)
  63. Additional file 17 of Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia
    Dan Xia, Lianoglou, Steve, Thomas Sandmann, Meredith Calvert, Jung H. Suh, Elliot R. Thomsen, Jason C. Dugas, Michelle E. Pizzo, Sarah L. DeVos, Timothy Earr et al. · 2022 · Figshare
  64. Additional file 10 of Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia
    Dan Xia, Lianoglou, Steve, Thomas Sandmann, Meredith Calvert, Jung H. Suh, Elliot R. Thomsen, Jason C. Dugas, Michelle E. Pizzo, Sarah L. DeVos, Timothy Earr et al. · 2022 · Figshare
  65. Additional file 9 of Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia
    Dan Xia, Lianoglou, Steve, Thomas Sandmann, Meredith Calvert, Jung H. Suh, Elliot R. Thomsen, Jason C. Dugas, Michelle E. Pizzo, Sarah L. DeVos, Timothy Earr et al. · 2022 · Figshare
  66. Mouse models of Alzheimer’s disease pathology
    Sunwoo Kim, Nora E. Gray · 2025 · Elsevier eBooks
  67. Glial Dysfunction in Alzheimer's Disease: Contributions to Disease Progression, Pathomechanism and Therapeutic Opportunities.
    Ina Dreschnack, Paul A. Dreschnack · 2025 · Medical Research Archives
  68. Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population
    Jason K Russell, Zinayida Schlachetzki, Michael S. Rafii · 2026 · Current Opinion in Neurology
  69. Probing APP Cleavage and Amyloid-β Assembly via Synthetic MUC-Type O -Glycosylated APP Glycopeptides
    Nancy Vela, Gustavo De Nadai Mundim, Deepika Regmi, Ivet Boneva, Ramya Ayyalasomayajula, Maria E. Vezzi, Valentina Sopo Borraez, Alexis Crowder, Alejandra Coronel-Zegarra, Hasham Shafi et al. · 2026 · ACS Chemical Neuroscience
  70. Implication du complexe récepteur 5-HT4/APP/ADAM10 dans la voie non-amyloïdogénique de la maladie d’Alzheimer
    Maud Cochet · 2011 · theses.fr (ABES)
  71. Synaptic modifications in hippocampal CA3 pyramidal cells in an Alzheimer's mouse model
    Pei Zhang · 2017 · theses.fr (ABES)
  72. Métalloprotéases matricielles et maladie d'Alzheimer : étude des rôles de MT1- et MT5-MMP dans l'amyloïdogenèse et la neuro-inflammation
    Jean‐Michel Paumier · 2018 · theses.fr (ABES)
  73. Altérations des synapses et des corps cellulaires neuronaux chez les souris APPxPS1-KI et dans la Maladie d'Alzheimer
    Alexandre Androuin · 2018 · theses.fr (ABES)
  74. Les APP-CTFs au cœur du processus pathologique de la maladie d’Alzheimer : contribution du système lysosomal-autophagique et de la sécrétion exosomale
    Anaïs Bécot · 2019 · theses.fr (ABES)
  75. MT5-MMP promotes neuroinflammation, pathogenic processing of amyloid precursor protein and synaptic dysfunction at early stages in an Alzheimer's disease model
    Dominika Piłat · 2021 · theses.fr (ABES)
  76. Comparaison des effets de la viniférine et du resvératrol dans des modèles expérimentaux de la maladie d'Alzheimer
    Aline Freyssin · 2020 · theses.fr (ABES)
  77. Impact of α-synuclein fibrillar strains and ß-amyloid assemblies on cultured mouse cortical neurons endo-lysosomal logistics
    Qiao-Ling Chou · 2021 · theses.fr (ABES)
  78. Computational fragment-based design of chemically modified oligonucleotides for selective protein inhibition : BACE1 as a case study
    Roy González‐Alemán · 2023
  79. Contribution à l'étude des facteurs de risque pour la maladie d'Alzheimer : analyse de candidats identifiés par étude d'association pangénomique ou GWAS
    Charlotte Bauer · 2023 · theses.fr (ABES)
  80. Histoire évolutive du plus ancien gène d’enveloppe rétrovirale endogène HEMO encore codant chez l’homme, exprimé dans le placenta et les tumeurs : acquisition récente d’une interaction avec une protéase transmembranaire chez les primates
    Anthony Béguin · 2024 · theses.fr (ABES)
  81. Etude des mécanismes physiοpathοlοgiques de la maladie d'Alzheimer : appοrt de l'étude des variants du gène SΟRL1
    Romain Castelot · 2024 · theses.fr (ABES)
  82. Intracellular protein GBF1 displays significant associations with amyloid pathology in Alzheimer's disease
    Sean J. Miller, Dmitry Prokopenko, Ping Bai, Prasenjit Mondal, Abigael Scott, Wei Zhang, Ashley Gomm, Siyi Zhang, Daniel D. Child, Nolan Shen et al. · 2026 · Alzheimer s & Dementia
  83. Beta-Secretase Inhibitors
    Justyna A. Dobrowolska Zakaria, Robert J. Vassar · 2026 · Topics in medicinal chemistry
  84. Advances and Limitations of Rodent Models in Alzheimer’s Disease Pathogenesis and Therapeutics
    Abhinav Singh, Lena Duerner · 2026 · Science Discovery Medicine
  85. Animal Models of Genetically-Determined Neurodegenerative Diseases and Their Development
    Ayumu Konno, Yasunori Matsuzaki, Hirokazu Hirai · 2026 · Contemporary clinical neuroscience
  86. Neuronal overexpression of Nrf2 reduces dystrophic neurites in 5XFAD Alzheimer’s disease model mice
    Katherine R. Sadleir, Karen P Gomez, Sidhanth Chandra, Makenna L. Ley, Ammaarah W. Khatri, Joanna Guo, Yunlu Xue, Constance L. Cepko, Robert J. Vassar · 2026 · Alzheimer s Research & Therapy
  87. De novo formation of familial Alzheimer’s disease-relevant Aβ strains occurs exclusively in the human brain
    Alison Mao, Alejandro Ruiz‐Riquelme, Marim M. Barghash, Nicholas R. G. Silver, Heather H. C. Lau, Erica Stuart, Silvia Zampar, Dag Sehlin, Stina Syvänen, Michael S. Pollanen et al. · 2026 · Acta Neuropathologica Communications
  88. Mechanisms of Aβ1-42-mediated oxidative stress-induced neuronal apoptosis in neonatal hypoxic-ischemic brain injury
    Li-Xuan Hou, Li-Hua Li · 2026 · Pediatrics & Neonatology
  89. PrPC limits APP delivery to the plasma membrane and alters its processing to facilitate Aβ release
    Nikita A. Mehta, Sungro Jo, Stanislau Smirnou, Gopal Thinakaran, James A. Mastrianni · 2026 · Neurobiology of Disease
  90. Swedish APP follows distinct neuronal trafficking itineraries that underlie its increased β-cleavage
    Cameron R. Plowinske, Sarah Tedesco, Alec T. Nabb, Geraldine B. Quinones, Marvin Bentley · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  91. Structural biology of protein misfolding and aggregation: from disease to therapeutic innovations
    Neha Kausar Ansari, Aabgeena Naeem · 2026 · Elsevier eBooks
  92. BindingDB Entry 50036937: Secretase targets for Alzheimer's disease: identification and therapeutic potential.
    BindingDB · 2012 · UC San Diego
  93. BindingDB Entry 50043934: Discovery of 7-tetrahydropyran-2-yl chromans:ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloidß-protein (Aß) in the central nervous system.
    BindingDB · 2014 · UC San Diego
  94. BindingDB Entry 50044864: 8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors.
    BindingDB · 2016 · UC San Diego
  95. BindingDB Entry 50044847: Lead optimization and modulation of hERG activity in a series of aminooxazoline xantheneß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
    BindingDB · 2016 · UC San Diego
  96. BindingDB Entry 50042875: Spirocyclicß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloidß in a higher species.
    BindingDB · 2013 · UC San Diego
  97. Ectodomain Mutations Alter the Proteolysis of the Amyloid-β Precursor Protein (APP)
    Michael Mitsumori · 2015
  98. Identification of the physiologically relevant α-secretase of the Alzheimer’s disease-related amyloid precursor protein and its relationship with β-secretase
    Huanhuan Wang · 2012 · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)